175 related articles for article (PubMed ID: 22937829)
21. VEGF-C, VEGF-D and VEGFR-3 expression in peripheral neuroblastic tumours.
Ramani P; Nash R; Radevsky L; Patel A; Luckett M; Rogers C
Histopathology; 2012 Dec; 61(6):1006-16. PubMed ID: 22804730
[TBL] [Abstract][Full Text] [Related]
22. Lymphangiogenesis and its regulation in human neuroblastoma.
Lagodny J; Jüttner E; Kayser G; Niemeyer CM; Rössler J
Biochem Biophys Res Commun; 2007 Jan; 352(2):571-7. PubMed ID: 17140547
[TBL] [Abstract][Full Text] [Related]
23. New model of in-situ xenograft lymphangiogenesis by a human colonic adenocarcinoma cell line in nude mice.
Sun JJ; Jing W; Ni YY; Yuan XJ; Zhou HH; Fan YZ
Asian Pac J Cancer Prev; 2012; 13(6):2823-8. PubMed ID: 22938466
[TBL] [Abstract][Full Text] [Related]
24. Expression of vascular endothelial growth factors VEGF- C and D, VEGFR-3, and comparison of lymphatic vessels density labeled with D2-40 antibodies as a prognostic factors in vulvar intraepithelial neoplasia (VIN) and invasive vulvar cancer.
Jach R; Dyduch G; Radon-Pokracka M; Przybylska P; Mika M; Dulinska-Litewka J; Zajac K; Huras H; Streb J; Stangel-Wojcikiewicz K; Dziadek O; Galarowicz B
Neuro Endocrinol Lett; 2011; 32(4):530-9. PubMed ID: 21876509
[TBL] [Abstract][Full Text] [Related]
25. Vascular endothelial growth factors C and D and lymphangiogenesis at the early stage of esophageal squamous cell carcinoma progression.
Kumagai Y; Tachikawa T; Higashi M; Sobajima J; Takahashi A; Amano K; Fukuchi M; Ishibashi K; Mochiki E; Yakabi K; Tamaru J; Ishida H
Dis Esophagus; 2018 Aug; 31(8):. PubMed ID: 29800478
[TBL] [Abstract][Full Text] [Related]
26. Neuroblastoma progression correlates with downregulation of the lymphangiogenesis inhibitor sVEGFR-2.
Becker J; Pavlakovic H; Ludewig F; Wilting F; Weich HA; Albuquerque R; Ambati J; Wilting J
Clin Cancer Res; 2010 Mar; 16(5):1431-41. PubMed ID: 20179233
[TBL] [Abstract][Full Text] [Related]
27. Differential expression of VEGF ligands and receptors in prostate cancer.
Woollard DJ; Opeskin K; Coso S; Wu D; Baldwin ME; Williams ED
Prostate; 2013 May; 73(6):563-72. PubMed ID: 23038639
[TBL] [Abstract][Full Text] [Related]
28. A potential small-molecule synthetic antilymphangiogenic agent norcantharidin inhibits tumor growth and lymphangiogenesis of human colonic adenocarcinomas through blocking VEGF-A,-C,-D/VEGFR-2,-3 "multi-points priming" mechanisms in vitro and in vivo.
Li XP; Jing W; Sun JJ; Liu ZY; Zhang JT; Sun W; Zhu W; Fan YZ
BMC Cancer; 2015 Jul; 15():527. PubMed ID: 26187792
[TBL] [Abstract][Full Text] [Related]
29. Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth.
Laakkonen P; Waltari M; Holopainen T; Takahashi T; Pytowski B; Steiner P; Hicklin D; Persaud K; Tonra JR; Witte L; Alitalo K
Cancer Res; 2007 Jan; 67(2):593-9. PubMed ID: 17234768
[TBL] [Abstract][Full Text] [Related]
30. Effect of local hyperthermia on lymphangiogenic factors VEGF-C and -D in a nude mouse xenograft model of tongue squamous cell carcinoma.
Liang X; Zhou H; Liu X; He Y; Tang Y; Zhu G; Zheng M; Yang J
Oral Oncol; 2010 Feb; 46(2):111-5. PubMed ID: 20036606
[TBL] [Abstract][Full Text] [Related]
31. TNF-alpha promotes lymphangiogenesis and lymphatic metastasis of gallbladder cancer through the ERK1/2/AP-1/VEGF-D pathway.
Hong H; Jiang L; Lin Y; He C; Zhu G; Du Q; Wang X; She F; Chen Y
BMC Cancer; 2016 Mar; 16():240. PubMed ID: 26992854
[TBL] [Abstract][Full Text] [Related]
32. [Vascular endothelial growth factor (VEGF)-D in association with VEGF receptor-3 in lymphatic metastasis of breast cancer].
Chen YN; Gu Y
Ai Zheng; 2009 Dec; 28(12):1337-43. PubMed ID: 19958632
[TBL] [Abstract][Full Text] [Related]
33. Lymphangiogenic growth factor responsiveness is modulated by postnatal lymphatic vessel maturation.
Karpanen T; Wirzenius M; Mäkinen T; Veikkola T; Haisma HJ; Achen MG; Stacker SA; Pytowski B; Ylä-Herttuala S; Alitalo K
Am J Pathol; 2006 Aug; 169(2):708-18. PubMed ID: 16877368
[TBL] [Abstract][Full Text] [Related]
34. Expression of vascular endothelial growth factor (VEGF)-C and -D in gastric carcinoma.
Shida A; Fujioka S; Kobayashi K; Ishibashi Y; Nimura H; Mitsumori N; Yanaga K
Int J Clin Oncol; 2006 Feb; 11(1):38-43. PubMed ID: 16508727
[TBL] [Abstract][Full Text] [Related]
35. Effects of fatty acid synthase inhibitors on lymphatic vessels: an in vitro and in vivo study in a melanoma model.
Bastos DC; Paupert J; Maillard C; Seguin F; Carvalho MA; Agostini M; Coletta RD; Noël A; Graner E
Lab Invest; 2017 Feb; 97(2):194-206. PubMed ID: 27918556
[TBL] [Abstract][Full Text] [Related]
36. Blockade of prolymphangiogenic vascular endothelial growth factor C in dry eye disease.
Goyal S; Chauhan SK; Dana R
Arch Ophthalmol; 2012 Jan; 130(1):84-9. PubMed ID: 21911653
[TBL] [Abstract][Full Text] [Related]
37. Rapamycin, a specific inhibitor of the mammalian target of rapamycin, suppresses lymphangiogenesis and lymphatic metastasis.
Kobayashi S; Kishimoto T; Kamata S; Otsuka M; Miyazaki M; Ishikura H
Cancer Sci; 2007 May; 98(5):726-33. PubMed ID: 17425689
[TBL] [Abstract][Full Text] [Related]
38. The connection between lymphangiogenic signalling and prostaglandin biology: a missing link in the metastatic pathway.
Karnezis T; Shayan R; Fox S; Achen MG; Stacker SA
Oncotarget; 2012 Aug; 3(8):893-906. PubMed ID: 23097685
[TBL] [Abstract][Full Text] [Related]
39. IGFBP7 functions as a potential lymphangiogenesis inducer in non-small cell lung carcinoma.
Zhao W; Wang J; Zhu B; Duan Y; Chen F; Nian W; Sun J; Zhang B; Tong Z; Chen Z
Oncol Rep; 2016 Mar; 35(3):1483-92. PubMed ID: 26706909
[TBL] [Abstract][Full Text] [Related]
40. circEHBP1 promotes lymphangiogenesis and lymphatic metastasis of bladder cancer via miR-130a-3p/TGFβR1/VEGF-D signaling.
Zhu J; Luo Y; Zhao Y; Kong Y; Zheng H; Li Y; Gao B; Ai L; Huang H; Huang J; Li Z; Chen C
Mol Ther; 2021 May; 29(5):1838-1852. PubMed ID: 33545359
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
